KRONOS BIO INC. - COMMON STOCK

Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)

04 мар 2021 07:00:01 Источник Nasdaq GlobeNewswire

Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

25 фев 2021 08:00:01 Источник Nasdaq GlobeNewswire

Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

26 янв 2021 08:00:02 Источник Nasdaq GlobeNewswire